---
created: '2026-02-13T18:17:34.698559Z'
description: Seed Amplification Assay (formerly RT-QuIC) that detects misfolded alpha-synuclein
  in CSF or tissue with >95% sensitivity and specificity for synucleinopathies. FDA
  approved in 2024, revolutionizing Parkinson's disease diagnosis.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/examination/alpha-synuclein-saa/
slug: alpha-synuclein-saa
tags:
- examination
- biomarker
- cutting-edge
- parkinsons
- synucleinopathy
- fda-approved
templateEngineOverride: njk
title: Alpha-Synuclein SAA
type: examination
updated: '2026-02-13T18:17:34.698559Z'
---

{% raw %}
<h1>Alpha-Synuclein Seed Amplification Assay (αSyn-SAA)</h1>
<h2>Overview</h2>
<p>Alpha-Synuclein Seed Amplification Assay (αSyn-SAA, formerly RT-QuIC) is a revolutionary diagnostic test that detects misfolded alpha-synuclein aggregates by amplifying trace amounts of pathological &quot;seeds&quot; in biological samples. With &gt;95% sensitivity and specificity for synucleinopathies, this test provides the first objective biological confirmation of Parkinson's disease. FDA approval in 2024 represents a paradigm shift from purely clinical diagnosis.</p>
<h2>Technology Principles</h2>
<h3>Seed Amplification</h3>
<ol>
<li>Patient sample (CSF) contains misfolded α-synuclein seeds</li>
<li>Added to reaction with recombinant α-synuclein substrate</li>
<li>Seeds template misfolding of substrate (prion-like)</li>
<li>Aggregation detected via thioflavin T fluorescence</li>
<li>Positive = exponential fluorescence increase</li>
</ol>
<h3>Key Metrics</h3>
<ul>
<li><strong>Fluorescence threshold crossing</strong>: Positive indicator</li>
<li><strong>Time to threshold</strong>: May correlate with disease</li>
<li><strong>Maximum fluorescence</strong>: Aggregate amount</li>
</ul>
<h2>FDA Approval (2024)</h2>
<h3>SYNTap Biomarker Test (Amprion)</h3>
<ul>
<li>First FDA-approved synuclein biomarker</li>
<li>CSF-based test</li>
<li>Indicated for synucleinopathy detection</li>
<li>93% sensitivity, 96% specificity in trials</li>
</ul>
<h3>Clinical Indication</h3>
<ul>
<li>Patients with parkinsonism of uncertain etiology</li>
<li>Differentiation from non-synuclein conditions</li>
<li>Prodromal/at-risk individuals (REM sleep behavior disorder)</li>
</ul>
<h2>Clinical Performance</h2>
<h3>Sensitivity and Specificity</h3>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson's disease</td>
<td>87-98%</td>
<td>90-100%</td>
</tr>
<tr>
<td>DLB</td>
<td>90-96%</td>
<td>90-100%</td>
</tr>
<tr>
<td>MSA</td>
<td>70-95%</td>
<td>90-100%</td>
</tr>
<tr>
<td>Controls (healthy)</td>
<td>0-5%</td>
<td>95-100%</td>
</tr>
<tr>
<td>AD/FTD (non-synuclein)</td>
<td>2-8%</td>
<td>92-98%</td>
</tr>
</tbody>
</table>
<h3>Prodromal Detection</h3>
<ul>
<li><strong>Isolated REM sleep behavior disorder</strong>: 85-95% positive</li>
<li>Predicts conversion to clinical PD/DLB</li>
<li>Years before motor symptoms</li>
<li>Enables early intervention trials</li>
</ul>
<h2>Sample Types</h2>
<h3>CSF (Primary - FDA Approved)</h3>
<ul>
<li>Gold standard for αSyn-SAA</li>
<li>Collected via lumbar puncture</li>
<li>Highest sensitivity</li>
<li>~10 mL needed</li>
</ul>
<h3>Skin Biopsy (Emerging)</h3>
<ul>
<li>Detects α-synuclein in cutaneous nerves</li>
<li>Less invasive than LP</li>
<li>Studies show 90%+ sensitivity</li>
<li>Not yet FDA approved</li>
<li>Punch biopsy technique</li>
</ul>
<h3>Other (Research)</h3>
<ul>
<li>Olfactory mucosa</li>
<li>Submandibular gland</li>
<li>GI mucosal biopsy</li>
<li>Blood (challenging, under development)</li>
</ul>
<h2>Clinical Applications</h2>
<h3>Diagnostic Confirmation</h3>
<ol>
<li><strong>Uncertain parkinsonism</strong>: Is it a synucleinopathy?</li>
<li><strong>Tremor differential</strong>: Essential tremor vs. PD</li>
<li><strong>Atypical presentation</strong>: Young onset, atypical features</li>
<li><strong>Drug-induced vs. degenerative</strong>: Medication effect vs. disease</li>
</ol>
<h3>Prodromal/At-Risk Screening</h3>
<ol>
<li><strong>REM sleep behavior disorder</strong>: High conversion risk</li>
<li><strong>Hyposmia + constipation</strong>: Early non-motor features</li>
<li><strong>LRRK2/GBA carriers</strong>: Genetic risk stratification</li>
<li><strong>Research cohorts</strong>: Trial enrichment</li>
</ol>
<h3>Differentiation</h3>
<table>
<thead>
<tr>
<th>Comparison</th>
<th>αSyn-SAA Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD vs. Essential Tremor</td>
<td>Positive vs. Negative</td>
</tr>
<tr>
<td>PD vs. Drug-induced</td>
<td>Positive vs. Negative</td>
</tr>
<tr>
<td>PD vs. Vascular parkinsonism</td>
<td>Positive vs. Negative</td>
</tr>
<tr>
<td>DLB vs. AD</td>
<td>Positive vs. Negative</td>
</tr>
<tr>
<td>MSA vs. PD</td>
<td>Both positive (distinct kinetics in some studies)</td>
</tr>
</tbody>
</table>
<h2>Relationships</h2>
<h3>Conditions (Positive SAA)</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/parkinsons-disease/" class="internal-link">Parkinson's Disease</a> (condition) - <em>Confirmatory test</em></li>
<li>→ <a href="/garden/dev_admin/condition/lewy-body-dementia/" class="internal-link">Lewy Body Dementia</a> (condition) - <em>High sensitivity</em></li>
<li>→ <a href="/garden/dev_admin/condition/multiple-system-atrophy/" class="internal-link">Multiple System Atrophy</a> (condition) - <em>Usually positive</em></li>
<li>→ <a href="/garden/dev_admin/condition/rem-sleep-behavior-disorder/" class="internal-link">REM Sleep Behavior Disorder</a> (condition) - <em>Prodromal marker</em></li>
</ul>
<h3>Conditions (Negative SAA)</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/essential-tremor/" class="internal-link">Essential Tremor</a> (condition) - <em>Helps exclude PD</em></li>
<li>→ <a href="/garden/dev_admin/condition/progressive-supranuclear-palsy/" class="internal-link">Progressive Supranuclear Palsy</a> (condition) - <em>Negative (tauopathy)</em></li>
<li>→ <a href="/garden/dev_admin/condition/corticobasal-degeneration/" class="internal-link">Corticobasal Degeneration</a> (condition) - <em>Negative (tauopathy)</em></li>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimer's Disease</a> (condition) - <em>Negative (unless Lewy copathology)</em></li>
</ul>
<h3>Related Biomarkers</h3>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament Light Chain</a> (biomarker) - <em>Neurodegeneration complement</em></li>
<li>→ <a href="/garden/dev_admin/examination/dat-spect/" class="internal-link">DAT-SPECT</a> (examination) - <em>Dopamine imaging</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/blood-nfl/" class="internal-link">Blood NfL</a> (biomarker) - <em>Accessible complement</em></li>
</ul>
<h3>Pathways</h3>
<ul>
<li>→ <a href="/garden/dev_admin/pathway/alpha-synuclein-aggregation/" class="internal-link">Alpha-Synuclein Aggregation</a> (pathway) - <em>Directly detected</em></li>
</ul>
<h2>Integration with Other Diagnostics</h2>
<h3>Proposed Diagnostic Algorithm (2025)</h3>
<pre><code>Clinical Parkinsonism
        ↓
    αSyn-SAA (CSF)
        ↓
   ┌────┴────┐
Positive    Negative
   ↓           ↓
Synucleinopathy   Non-synuclein
confirmed         Consider:
   ↓              - PSP, CBD (tau)
DAT-SPECT if      - Vascular
needed for        - Drug-induced
subtype           - Essential tremor
</code></pre>
<h3>NSD-ISS Criteria (2024)</h3>
<ul>
<li>New PD classification integrating SAA</li>
<li>Biological definition of disease</li>
<li>Stages based on biomarkers + symptoms</li>
</ul>
<h2>Advantages and Limitations</h2>
<h3>Advantages</h3>
<ul>
<li><strong>Objective biological diagnosis</strong> (vs. clinical alone)</li>
<li><strong>Very high accuracy</strong> (&gt;95%)</li>
<li><strong>Prodromal detection</strong> (years before motor symptoms)</li>
<li><strong>FDA approved</strong> (clinical implementation)</li>
<li><strong>Differentiates from mimics</strong></li>
</ul>
<h3>Limitations</h3>
<ul>
<li>Requires lumbar puncture (CSF)</li>
<li>MSA may differ from PD/DLB kinetics</li>
<li>Cannot distinguish PD from DLB</li>
<li>Rare false positives in very elderly</li>
<li>Cost and availability still limited</li>
</ul>
<h2>Future Directions</h2>
<h3>Blood-Based SAA</h3>
<ul>
<li>Active research area</li>
<li>Neuronal exosomes as sample</li>
<li>Early results promising but challenging</li>
<li>Would eliminate LP requirement</li>
</ul>
<h3>Skin Biopsy Validation</h3>
<ul>
<li>Less invasive than LP</li>
<li>Multi-site studies ongoing</li>
<li>Potential office-based procedure</li>
</ul>
<h3>Treatment Trials</h3>
<ul>
<li>Enrich trials with SAA-confirmed disease</li>
<li>Track aggregation as outcome</li>
<li>Enable prevention trials in prodromal</li>
</ul>
<h2>References</h2>
<ol>
<li><strong>FDA Approval</strong>: Amprion SYNTap Biomarker Test (2024). FDA News Release.</li>
<li><strong>Validation</strong>: Siderowf, A., et al. (2023). &quot;α-Synuclein SAA in PPMI cohort.&quot; <em>The Lancet Neurology</em>.</li>
<li><strong>Prodromal</strong>: Iranzo, A., et al. (2021). &quot;αSyn-SAA in isolated RBD.&quot; <em>The Lancet Neurology</em>.</li>
<li><strong>NSD-ISS Criteria</strong>: Höglinger, G.U., et al. (2024). &quot;A biological classification of PD.&quot; <em>The Lancet Neurology</em>.</li>
</ol>

{% endraw %}